Despite several case reports indicating promising therapeutic benefits with IL-17 antagonists, a recent phase III trial evaluating the efficacy of secukinumab in patients with active lupus nephritis was terminated following an interim analysis for futility, with no safety concerns identified (5). Here, IL17A is linked to lupus nephritis.